Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Investing.com-- Australian shares of Resmed (NYSE: RMD) Inc DRC (ASX: RMD) hit a record high on Friday after the medical ...

But within weeks, Novo Nordisk’s partnership crumbled amid a messy war of words. Novo Nordisk accused Hims & Hers of continuing to deceptively sell large volumes of copycat vers ...

The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Resmed beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea.

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...